HNF4A: Hepatocyte nuclear factor 4-alpha
Transcriptional regulator which controls the expression of hepatic genes during the transition of endodermal cells to hepatic progenitor cells, facilitating the recruitment of RNA pol II to the promoters of target genes.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on HNF4A, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Carvedilol and Alverine in Portal Hypertension | Alverine | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Changzheng Hospital | Nov 20, 2024 |
| Ebastine Versus Mebeverine in IBS Patients | Alverine | Phase 3 | Active, not recruiting | Guy Boeckxstaens | Apr 18, 2023 |
| The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study | Alverine | Phase 2 | Enrolling by invitation | Shanghai Changzheng Hospital | Aug 19, 2022 |
| The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) | Alverine | Not applicable | Not yet recruiting | University of Pecs | Oct 29, 2021 |
| Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome | Alverine | Phase 3 | Recruiting | Tanta University | Jan 3, 2020 |
- Maturity-onset diabetes of the young0.82
- Type 2 diabetes mellitus0.80
- Renal cysts and diabetes syndrome0.74
- Diabetes mellitus0.68
- Monogenic diabetes0.68
- Cholelithiasis0.55
- Intrahepatic cholestasis of pregnancy0.52
- Gallstones0.51
- Metabolic syndrome0.50
- Cholecystitis0.48
- Gastrointestinal disease0.46
- Hyperinsulinism due to HNF4A deficiency0.45
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5398, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P41235, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets